Piotr Garnuszek Selected Research

177Lu-DOTA-rituximab

10/2020

Impact of DOTA-Chelators on the Antitumor Activity of 177Lu-DOTA-Rituximab Preparations in Lymphoma Tumor-Bearing Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Piotr Garnuszek Research Topics

Disease

9	Neoplasms (Cancer) 12/2022 - 02/2002
5	Prostatic Neoplasms (Prostate Cancer) 10/2021 - 08/2009
5	Thyroid Neoplasms (Thyroid Cancer) 01/2019 - 03/2016
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2022 - 01/2015
2	Neoplasm Metastasis (Metastasis) 03/2021 - 04/2003
2	Adenocarcinoma 07/2008 - 01/2005
1	Primary Myelofibrosis (Myelosclerosis) 05/2021
1	Lymphoma (Lymphomas) 10/2020
1	Infections 01/2017
1	Inflammation (Inflammations) 01/2017
1	Insulinoma 01/2016
1	Heart Diseases (Heart Disease) 04/2012
1	Atherosclerotic Plaque (Atheroma) 04/2012
1	Chronic Kidney Failure (Chronic Renal Failure) 04/2012
1	Experimental Neoplasms 07/2008
1	Colonic Neoplasms (Colon Cancer) 01/2004
1	Pain (Aches) 04/2003
1	Spondylarthropathies 04/2003
1	Breast Neoplasms (Breast Cancer) 01/2002

Drug/Important Bio-Agent (IBA)

4	Peptides (Polypeptides)IBA 01/2019 - 01/2005
4	RadiopharmaceuticalsIBA 01/2017 - 04/2003
4	PlatinumIBA 07/2008 - 01/2002
3	Biological ProductsIBA 12/2022 - 02/2002
3	Radioisotopes (Radionuclides)IBA 04/2018 - 01/2004
3	Cytostatic AgentsIBA 07/2008 - 01/2002
2	Rituximab (Mabthera)FDA Link 12/2022 - 01/2015
2	Chelating AgentsIBA 12/2022 - 10/2020
2	LigandsIBA 10/2021 - 03/2021
2	BombesinIBA 01/2021 - 08/2009
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 10/2020 - 08/2009
2	Cholecystokinin B ReceptorIBA 12/2018 - 03/2016
2	Cholecystokinin (Pancreozymin)IBA 08/2016 - 03/2016
2	Histamine (Histamine Dihydrochloride)FDA Link 07/2008 - 01/2004
1	Monoclonal AntibodiesIBA 12/2022
1	GalliumIBA 10/2021
1	AntigensIBA 10/2021
1	EnzymesIBA 05/2021
1	yttrium(III)- 1,4,7,10- tetraazacyclotetradecane- N,N',N'',N'''- tetraacetic acidIBA 01/2021
1	Somatostatin Receptors (Somatostatin Receptor)IBA 12/2020
1	177Lu-DOTA-rituximabIBA 10/2020
1	DOTA-NHSIBA 10/2020
1	Pharmaceutical PreparationsIBA 01/2019
1	Cholecystokinin Receptors (Cholecystokinin Receptor)IBA 04/2018
1	Technetium (Technetium 99m)IBA 01/2017
1	exametazime FDA Link 01/2017
1	GastrinsIBA 08/2016
1	minigastrinIBA 03/2016
1	Exenatide (Byetta)FDA Link 01/2016
1	EDDA (NiEDDA)IBA 01/2016
1	Interleukin-2 (IL2)IBA 04/2012
1	Gastrin-Releasing PeptideIBA 08/2009
1	IodineIBA 07/2008
1	Proteins (Proteins, Gene)FDA Link 01/2005
1	AcidsIBA 04/2003
1	ethylenediamine (ethylenediamine dihydroiodide)FDA Link 04/2003
1	technetium Tc 99m ethylenediamine-tetramethylenephosphonic acidIBA 04/2003
1	Cisplatin (Platino)FDA LinkGeneric 02/2002

Therapy/Procedure

5	Therapeutics 10/2021 - 04/2018
3	Precision Medicine 01/2021 - 04/2018
3	Radiotherapy 08/2009 - 02/2002
2	Radioimmunotherapy 12/2022 - 10/2020
1	Palliative Care (Palliative Therapy) 10/2021
1	Castration 05/2021
1	Drug Therapy (Chemotherapy) 02/2002
1	Intraperitoneal Injections 02/2002